← Back to patent-cliff list
Vicadrostat
Tier C — Watch / tradeVicadrostat
Boehringer Ingelheim
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP11B2
Indications (approved)：Chronic renal impairment, Type 2 diabetes, Hypertension, Heart failure, Liver disease, Kidney disease, Diabetic nephropathy
Regional status
US
Phase III
2024-06-17
EU
Phase III
2024-06-17
China
Phase III
2024-06-17
Japan
Phase III
2024-06-17
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vicadrostat?
Approved indications include: Chronic renal impairment, Type 2 diabetes, Hypertension, Heart failure, Liver disease, Kidney disease, Diabetic nephropathy.
When does the Vicadrostat patent expire?
No public expiry year is available for Vicadrostat yet; this page updates once verified.
How do I get a quote for Vicadrostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01